

Longitudinal data modeling for Alzheimer's disease: Examples of Predictive and Generative models

Supervisor:
Prof. Dr. Martin Hofmann-Apitius
Co-supervisor:
Prof. Dr. Holger Fröhlich

Presented by:
Meemansa Sood

Alzheimer's Disease


- Understanding the pathophysiological process of the disease
- Stage specific disease progression
- Understanding the role of biomarkers in the predictive analyses of progression of disease



The figure is adapted from Jack, et. al. 2013

Scientific Challenge

- Understand and model diseases in a longitudinal manner
- Need to agglomerate and understand multi-scale data




- Issues:
 - Failure of several clinical trials around established hypotheses
 - Intermittent patient drop outs
 - Lack of enough neurological data

Machine Learning Strategies


Bayesian Networks (BNs)

- BNs give probabilistic relationships among a set of variables
- Generative as well as predictive model




- BN can model temporal processes
- Model can (partially) learn causal relationships from multi-modal data

Overview of Workflow





BN as generative model



- Unfolding of time dependent variables
- Constraints for possible edges


Results of BN Structure Learning



Variable Importances:

	variable	relative_importance
1	CDRSB.bl	1.000000
2	MMSE.bl	0.972977
3	ADAS11.bl	0.953378
4	FAQ.bl	0.928205
5	ADAS13.bl	0.908452
6	RAVLT.immediate.bl	0.723133
7	RAVLT.perc.forgetting.bl	0.571820
8	RAVLT.learning.bl	0.517162
9	RAVLT.forgetting.bl	0.026748

BN used as a predictive model




Virtual Patient Simulation

1

Comparison based on the distance measure

- Gower's generated dissimilarity matrix
- k nearest neighbours of each virtual patient determined (k = 9)*



- Develop a classifier

Conclusion

- Bayesian networks can be used for obtaining inter-dependencies among multivariate features
- Predict values of features at future time points from previous time points
- Quantitative evidence, can be further developed for data-driven virtual clinical trial and creation of virtual patients

Acknowledgement

- Akrishtha Sahay
- Reagon Karki
- Prof. Dr. Holger Fröhlich

Thank you